[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eeg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eeg":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,75,122,155,187,220,251,280,312,340,371,395,416,447,468,483,508],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100598420","study-of-the-correlation-between-cortical-excitability-and-cytoarchitectonics-of-prefrontal-cortex-in-healthy-adult-participants-using-transcranial-magnetic-stimulation-coupled-to-eeg-and-high-field-mri-100598420",false,"NCT07071259","Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI","FrontalProbe","Inclusion Criteria:\n\n* People aged 18 to 35\n* People affiliated with a social security scheme or beneficiary of such a scheme\n* People who have signed the informed consent\n* Right-handed people\n* People with a body mass index between 18 and 26\n* People able to abstain from alcohol for 24 hours prior to the experiment\n* People able to remain perfectly still for 15 minutes straight, and able to have reduced mobility for 3 hours\n* People able to of not using narcotics (marijuana, cocaine, ecstasy, MDMA, ketamine, etc.) during the 15 days preceeding the experiment.\n* Conducting a pregnancy test before inclusion for women of childbearing age and when the research is conducted over a long period, at a frequency adapted to the gaze of the research acts\n* Effective contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Pregnant, parturient, or breastfeeding\n* Protected adults\n* Minors\n* People staying in a healthcare or social institution\n* People in an emergency situation\n* People deprived of their liberty\n* People with the usual contraindications to MRI\n\n  * Ferromagnetic surgical clips, ocular implants, metallic foreign bodies intraocularly or in the nervous system, implants or metallic objects susceptible to concentrate the radio frequency field, cochlear implants, brain stimulator or cardiac pacemaker, presence of a craniotomy scar, agitation\n  * Claustrophobia\n  * Large, black tattoo close to the orofacial area\n* People not wishing to be informed of abnormalities discovered at the MRI\n* People with a history of epilepsy or suffering from epilepsy\n* Individuals whose parents, children, siblings, or parents have a history of epilepsy\n* People with known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Staff with a hierarchical link to the investigators",true,"ALL","18 Years","35 Years",{"count":21,"type":22},34,"ESTIMATED","INTERVENTIONAL",[25],"NA","Repeated transcranial magnetic stimulation (rTMS) is mainly used to treat mood disorders by addressing differences in brain function, particularly in the dorsolateral prefrontal cortex (DLPFC), which affects emotions and executive functions. The therapy aims to enhance the left DLPFC or suppress the right. It has been approved for severe major depression in several countries (Canada and Israel since 2002, USA since 2008) and is in the process of being validated in Europe but is not yet reimbursed in France. due to variable results from one study to another and lack of standardization issues.\n\nIn a previous study, by recording electroencephalographic (EEG) rhythms before and after rTMS treatment of the DLPFC, the investigators showed on a small cohort of patients (n=17) with major or bipolar depression, that the responder patients showed higher EEG theta rhythms in the DLPFC but also and especially in parietal regions. This suggests that the DLPFC is part of the fronto-parietal central executive network (CEN), which is important for working memory and cognitive control. The CEN is not well connected in severe resistant depression, possibly leading to negative emotional bias. The rTMS cure of DLPFC can be interpreted as improving depressive symptoms through the normalization of the CEN by increasing DLPFC excitability and its downward connectivity. However experimental and clinical evidence for this mechanism, among others, is still to be demonstrated, and remission rates of rTMS from DLPFC in drug-resistant depression are still low (20-40%).\n\nTo improve these response rates to rTMS in DLPFC, it is essential to continue research aimed at improving clinical practices through a better knowledge of the functional neuroanatomy and mechanisms of action of rTMS. This will require the definition of biomarkers allowing in particular to better target the DLPFC, this structure beeing indeed relatively poorly defined on the neuroanatomical level (large portion of the medial frontal gyrus). To this end, the investigators have set up a collaborative research program with Dr. Corey Keller, psychiatrist at Stanford University USA, which was jointly funded in 2022 by the Agence Nationale pour la Recherche (ANR) and the National Institute of Health (NIH) - FrontalProbe project \"Probing the dorsolateral prefrontal cortex and central executive network for improving neuromodulation in depression\". The ultimate aim of this project is to develop and test different strategies for targeting the DLPFC in the rTMS treatment of pharmaco-resistant depressive patients, following the fundamental neuroanatomical and pathophysiological hypothesis that patients will respond better to therapy if their CEN network is better modulated. This clinical trial will take place in Stanford, USA, in the years 2025-2026. Previously, the investigators are working on the development of methodological strategies aimed at preferentially activating, in a personalized way, the part of the DLPFC that projects onto the PPC. This is the subject of the present protocol, which aims to identify this subpart of the DLPFC to be targeted as a priority for modulating the CEN, through neuroanatomical measurements with high-field MRI and cortical excitability by TMS-EEG in healthy subjects. To this end, the investigators will use a small cohort of healthy subjects who will have one multimodal MRI acquisition session of at 7T and one TMS-EEG session. The 7T MRI data, acquired at the Centre de Résonance Magnétique en Biologie et Médecine (CRMBM), will be used to obtain anatomical markers of the DLPFC. TMS-EEG data, acquired at the Institut de Neurosciences de Systèmes (INS), will be used for cortical excitability measurements of the DLPFC and its projection sites, notably the PPC. At this stage, no data exchange is planned with our American partners.\n\nFirstly, the processing of MRI data will include segmentation of gray and white matter, reconstruction of the cortical surface and estimation of the different cortical layers, mainly by monitoring variations in the T1 parameter along the cortical mantle. Other MRI parameters will also be acquired to maximize the specificity of the segmentation of the DLPFC into sub-regions, firstly by identifying the part of the DLPFC that connects preferentially to the PPC using the reconstruction of fiber bundles from diffusion MRI and functional resting MRI. Secondly, during TMS-EEG acquisitions, participants will be stimulated in 3 sub-regions of the DLPFC. For each target, the analyses of the EEG data will focus on quantifying connectivity with the PPC as well as their spectral signature, which is possibly an indirect reflection of the neuronal composition of the stimulated regions.\n\nCorrelation of 7T MRI and TMS-EEG data will help set optimal DLPFC targeting criteria for PPC activation. The aim is to create an MRI-based targeting procedure for clinical practice. In this sense, TMS-EEG will serve as validation of MRI markers.",[28,29,30,31,32,33],"Healthy Participants","Magnetic Stimulation","MRI","EEG","Dorsolateral Prefrontal Cortex","rTMS Stimulation","NOT_YET_RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":22},"2026-07-15",{"date":42,"type":22},"2028-04",{"name":44,"class":45},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100636118","electrophysiological-biomarkers-and-treatment-response-to-accelerated-transcranial-magnetic-stimulation-in-patients-with-obsessive-compulsive-disorder-100636118","NCT07561528","Electrophysiological Biomarkers and Treatment Response to Accelerated Transcranial Magnetic Stimulation in Patients With Obsessive-Compulsive Disorder","Investigation of the Relationship Between Electrophysiological Biomarkers and Treatment Response in Patients Diagnosed With Obsessive-Compulsive Disorder Undergoing Transcranial Magnetic Stimulation Therapy","TMS-OCD-EEG","Inclusion Criteria:\n\n* Being between 18 and 65 years of age.\n* Being diagnosed with Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria.\n* Non-responsiveness to at least one Selective Serotonin Reuptake Inhibitor (SSRI) treatment at an adequate dose and duration.\n* Having a Y-BOCS score of ≥20 following the initial evaluation.\n* No change in the current medications within the last 2 months and a commitment to maintaining stable doses throughout the study.\n* Providing informed consent and having no contraindications for TMS.\n\nExclusion Criteria:\n\n* Severe neurological disorders or neurodegenerative diseases.\n* Any condition associated with increased seizure risk\n* History of cochlear implants, metal implants in the head and neck area, cardiac pacemakers, deep brain stimulation, or vagus nerve stimulation.\n* History of neurosurgical intervention.\n* General contraindications for Transcranial Magnetic Stimulation therapy.","65 Years",{"count":57,"type":22},30,[25],"Purpose:\n\nThis study aims to evaluate the effectiveness of an accelerated intermittent Theta Burst Stimulation (iTBS) protocol-a non-invasive brain stimulation technique-targeted at the dorsomedial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC) in patients with treatment-resistant Obsessive-Compulsive Disorder (OCD). Additionally, the study seeks to identify electrophysiological biomarkers (such as EEG microstates and heart rate variability) that may predict which patients are most likely to benefit from the treatment.\n\nMethodology:\n\nThe study will include 30 patients aged 18-65 diagnosed with OCD according to DSM-5 criteria who have not responded sufficiently to standard treatments. Participants will undergo an intensive 7-day treatment program consisting of 4 iTBS sessions per day (totaling 28 sessions). Clinical symptoms will be assessed before and after the treatment using standardized scales, including the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). Resting-state EEG measurements and heart rate data will be recorded during and after the sessions to analyze physiological changes.\n\nGoal:\n\nThe findings are expected to contribute to the development of personalized neuromodulation protocols and help identify predictors of treatment response for OCD patients.",[61,62,63,31],"Obsessive - Compulsive Disorder","Transcranial Magnetic Stimilation","Intermittent Theta Burst Stimulation","RECRUITING","2026-05-07",{"date":67,"type":38},"2026-05-08",{"date":69,"type":38},"2026-01-01",{"date":71,"type":22},"2027-04-01",{"name":73,"class":74},"Istanbul University - Cerrahpasa","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100629619","non-invasive-detection-and-preservation-of-neurocognitive-signals-in-the-peri-death-period-using-brain-computer-interface-and-artificial-intelligence-100629619","NCT07477028","Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence","Feasibility of Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence: A Prospective Observational Study (NeuroCogPresv)","NeuroCogPresv","Inclusion Criteria:\n\n1. Adults ≥18 years with terminal illness or severe acute trauma\n2. Do-not-resuscitate (DNR\u002FDNI) order in place\n3. Surrogate decision-maker available and willing to provide informed consent\n4. Expected survival ≤7 days (physician estimate)\n\nExclusion Criteria:\n\n1. Brain death already declared \\> 24 hours prior to enrollment\n2. Contraindication to EEG\u002FBCI headset placement (e.g., severe scalp injury)\n3. Patient lacks a legally authorized representative",{"count":84,"type":22},20,"OBSERVATIONAL","Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.\n\nObjectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.\n\nDesign: Prospective, open-label, multicenter, observational cohort (n\\>20).",[88,89,90,91,92,93,94,95,96,97,98,99,31,100],"Terminal Illness","End-of-Life Care","Death","Brain Death","Death Anxiety","Consciousness","Electroencephalography","Gamma Oscillations","Near-Death Phenomena","Cognitive","Cognition","Memory","Severe Acute Trauma",[102,103,104,90,95,98,93,105,106,107,99,108,109,110,111],"AI","BCI","Brain Computer Interface","Pefi-death","Brain death","Reservation","Life","Life experience","Transfer","Convergence","2026-03-12",{"date":114,"type":38},"2026-03-17",{"date":116,"type":22},"2026-09-01",{"date":118,"type":22},"2035-09-30",{"name":120,"class":121},"Noah Tech, Corp.","INDUSTRY",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":141,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":46},"100628929","dynamic-causal-modeling-of-neuromodulation-of-action-speed-via-targeted-tms-eeg-100628929","NCT07468032","Dynamic Causal Modeling of Neuromodulation of Action Speed Via Targeted TMS-EEG","NAS","Inclusion Criteria:\n\n* The control group consists of individuals who are :\n* neurologically healthy,\n* meaning they do not have any medical conditions that could interfere with cognitive performance or its measurement.\n* not have any contraindications for undergoing MRI scans or TMS, such as epilepsy, which could be triggered by magnetic stimulation.\n* The patient group will include :\n* individuals who have experienced a hemispheric stroke but with specific criteria ( stroke must not have affected key prefrontal regions that are targeted in the study, ensuring that the observed motor slowing is due to network dysfunction rather than direct structural damage to these regions)\n* be free of other cognitive impairments or medical conditions that could confound the study's results.\n\nExclusion Criteria:\n\n* participants with neurological,\n* psychiatric, or general conditions known to alter test performance or cognitive function, according to a previously validated method will be excluded.\n* any contraindication to MRI and TMS (e.g., epilepsy).\n* For stroke patients, the lesion delineated on MRI must spare the prefrontal target structures.",{"count":130,"type":22},80,[25],"Stroke is a major cause of long-term disability, with cognitive and motor deficits-especially action slowing and executive dysfunction-being strong predictors of poor recovery outcomes. Recent advances in network neuroscience suggest that action speed is governed by interactions between specific prefrontal and premotor regions. However, the precise neural mechanisms underlying action slowing in stroke remain unclear, limiting the efficacy of current rehabilitation approaches. This study integrates high-density EEG, fNIRS and dynamic causal modeling (DCM), and rTMS to map and modulate the neural circuits involved in action speed. In the first phase, we will assess the role of seven key brain regions in action speed modulation by applying virtual lesions using single-pulse TMS in 60 healthy individuals. In the second phase, we will apply offline intermittent theta burst stimulation (iTBS) to the most relevant regions and evaluate its impact on action speed. Finally, in the clinical phase, we will administer individualized iTBS to 20 stroke patients to enhance action speed. Patients will be assessed at baseline, immediately post-treatment, and after one and three months to track improvements in action speed using DCM and behavioral tests. Changes in connectivity and action speed performance will be compared to healthy controls to refine treatment parameters. Secondary outcomes include executive function and daily life motor performance. Longitudinal follow-up will determine the persistence of improvements, informing future personalized rehabilitation strategies. By characterizing effective connectivity changes post-stroke, we aim to refine neuromodulation strategies and develop a personalized rTMS approach. Our hypothesis is that targeting specific regions identified through integration of EEG, fNIRS and DCM can enhance action speed, ultimately improving functional recovery. This personalized approach could lead to more effective rehabilitation protocols, tailored to individual brain damage patterns.",[134,135,31,136,137,138,139,140],"Temporal Perturbation","Virtual Lesion","fNIRS","TMS","Stroke Lesions","Action Slowing","Stroke",[142,143,31,136,137,144,145,146],"Temporal perturbation","Virtual lesion","stroke lesions","action slowing","stroke","2026-03-10",{"date":112,"type":38},{"date":150,"type":38},"2026-01-06",{"date":152,"type":22},"2028-12",{"name":154,"class":74},"Centre Hospitalier Universitaire, Amiens",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":17,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100581431","observational-study-on-the-impact-of-obstructive-sleep-apnea-on-executive-function-and-empathy-development-in-children-100581431","NCT06850220","Observational Study on the Impact of Obstructive Sleep Apnea on Executive Function and Empathy Development in Children","OSA-EFED","Inclusion Criteria:\n\n* Children aged 3-12 years.\n* Diagnosed with OSA due to adenoid and\u002For tonsillar hypertrophy.\n* IQ ≥ 85.\n* Parental consent for participation.\n\nExclusion Criteria:\n\n* Other primary sleep disorders (e.g., narcolepsy, restless leg syndrome).\n* Developmental delay, epilepsy, or other neurological\u002Fmetabolic disorders.\n* Chronic diseases or history of head trauma.","3 Years","12 Years",{"count":165,"type":22},150,"This study aims to investigate the effects of obstructive sleep apnea (OSA) on executive function and empathy development in children aged 3-12 years. The study will compare the outcomes of different treatment approaches (surgical vs. pharmacological) in children with mild OSA and track the progression of cognitive and emotional functions over 12 months. The study will also explore potential EEG biomarkers for assessing neurological damage in OSA children.",[168,98,169,31],"Pediatric Obstructive Sleep Apnea","Empathy",[171,172,169,173,174,175,176,177],"Obstructive Sleep Apnea","Executive Function","Children","EEG Biomarkers","Cohort Study","Neurodevelopment","Adenotonsillectomy","2026-01-23",{"date":180,"type":38},"2026-01-26",{"date":182,"type":38},"2025-10-13",{"date":184,"type":22},"2027-06-30",{"name":186,"class":74},"Children's Hospital of Soochow University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":16,"sex":17,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100621326","neural-correlates-of-goal-directed-action-observation-and-execution-in-children-with-unilateral-cerebral-palsy-100621326","NCT07369167","Neural Correlates of Goal-directed Action Observation and Execution in Children With Unilateral Cerebral Palsy","Neurophysiological, Kinematics and Functional Correlates of Goal-directed Action Observation and Execution in Children With Unilateral Cerebral Palsy","EEG_AINCP","Children with Unilateral Cerebral Palsy\n\nInclusion Criteria:\n\n* Children with confirmed diagnosis of Unilateral Cerebral Palsy,\n* Manual ability levels from I to III in the Manual Ability Classification System (MACS);\n* Children's age from 5 to 15 years old.\n\nExclusion Criteria:\n\n* Severe Upper Limb (UpL) impairment (MACS ≥ level IV: inability to grasp),\n* UpL surgery within 12 months prior to study entry and botulinum toxin injection within 6 months prior to study entry,\n* Severe comobordities,\n* Severe cognitive disability, clinically assessed by the cognitive scales Wechsler, Preschool and Primary Scale of Intelligence (WPPSI-IV) or Wechsler Intelligence Scale for Children (WISC-IV or V).\n\nTypically Developing children:\n\nInclusion Criteria\n\n* 5 to 15 year-old children with typical development,\n* No documented clinically relevant disorders","5 Years","15 Years",{"count":130,"type":22},"Cerebral palsy (CP) is the most common childhood-onset motor disorder, with Unilateral Cerebral Palsy (UCP)- motor impairment predominantly impacting one side of the body-representing the most frequent form of CP. Among available rehabilitation programs, Action Observation Treatment (AOT) has gained increasing attention for its demonstrated effectiveness in improving manual motor function. AOT involves the systematic observation of goal-directed actions followed by their execution\u002Fimitation and is thought to leverage the mirror mechanism and its role in motor learning. Specifically, it relies on the neurophysiological principle that observing others' actions activates the same neural structures involved in executing those actions, reflecting the engagement of the mirror neuron system (MNS). In children with CP, the feasibility and effectiveness of AOT have been shown functionally (Sgandurra et al., 2013, Buchignani et al., 2019). However, despite its theoretical grounding in MNS functioning, the neurophysiological correlates of this system in children with CP remain less characterized, with only limited investigations using functional neuroimaging (e.g., Sgandurra et al., 2020) or neurophysiological methods such as electroencephalography (EEG; e.g., Demas et al., 2019).\n\nThis observational study aims to characterize the neurophysiological signatures of action execution and action observation in children aged 5-15 years with a diagnosis of UCP compared to a group of age-matched typically developing (TD) peers. To this end, non-invasive high-density EEG (hdEEG) will be used to quantify sensorimotor cortex modulation through mu-rhythm reactivity-specifically event-related desynchronization (ERD) and synchronization (ERS)-and its topographical distribution during an active visuo-motor task involving upper limbs. Mu-rhythm desynchronization (or suppression) over sensorimotor regions is a well-established marker of MNS engagement. A secondary objective is to examine the relationship between EEG measures and participants' attention, upper-limb kinematics, and manual motor function. To this purpose, participants will wear non-invasive wearable sensors to capture arm\u002Fhand kinematics, and attention will be monitored with a non-invasive eye-tracking system. Validated scales will be used to assess manual motor function.\n\nParticipants will take part in one single visit of about 1.5 hours. During the EEG acquisition session, children will wear a 128-channel EEG net and complete an active visuo-motor paradigm including the observation and execution of unimanual and bimanual goal-directed actions (e.g., reaching-grasping). In the observation condition, children will watch videos depicting these actions on a computer screen while refraining from movement. In the subsequent execution condition, they will interact themselves with the same objects as in the observation condition. Throughout the same session, children's attention\u002Fgaze will be tracked via eye-tracking, and upper-limb kinematics will be recorded using wearable inertial measurement unit (IMU) sensors. Before or after EEG acquisition, manual motor function will be assessed using two standardized scales: the Assisting Hand Assessment (AHA) and the Melbourne Assessment-2 (MA-2).\n\nData analysis will characterize the mu rhythm ERD topography and temporal dynamics during both action execution and action observation, within and between groups. Correlation analyses will explore associations between neurophysiological measures, gaze and attentional patterns, kinematic data, and motor assessments scores to elucidate how motor and attentional factors modulate sensorimotor cortical activation.",[200,201,31,202],"Cerebral Palsy (CP)","Unilateral Cerebral Palsy","Action Observation",[201,204,31,205,206,207,208,202,209,210],"Mirror Neuron System","Mu rhythm","Sensorimotor","eye-tracker","wearable sensors","manual function","UCP","2026-01-16",{"date":213,"type":38},"2026-01-27",{"date":215,"type":22},"2026-01",{"date":217,"type":22},"2027-07",{"name":219,"class":74},"IRCCS Fondazione Stella Maris",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":228,"minAge":18,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":46},"100608575","home-based-transcranial-direct-current-stimulation-tdcs-compared-to-duloxetine-non-inferiority-clinical-trial-fibrostim-100608575","NCT07203339","Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)","Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine in the Treatment of Fibromyalgia: a Randomized Non-inferiority Clinical Trial (FIBROSTIM)","FIBROSTIM","Eligibility Criteria\n\nInclusion Criteria:\n\n* Woman aged between 18 and 75 years\n* Right-handed\n* Literate in reading and writing\n* Clinical diagnosis of fibromyalgia based on the American College of Rheumatology (ACR) 2010-2016 criteria\n* Numeric Pain Scale (NPS) score ≥ 4 on most days in the past 30 days\n* Agree no changes in medication dosage during the treatment period (except for analgesics)\n* Able to swallow tablets\n* Able to understand instructions for using tDCS at home\n\nExclusion Criteria:\n\n* Living more than 250 km from Porto Alegre\n* Pregnancy\n* Decompensated systemic diseases\n* Chronic inflammatory rheumatologic diseases\n* Untreated hypothyroidism\n* Active cancer under treatment\n* Alcohol or drug abuse in the past 6 months\n* Decompensated psychiatric disorders with suicide risk and a defined plan\n* Use of duloxetine at a dose \\> 60 mg\u002Fday\n* Metal implants in the brain\n* Implanted brain medical devices\n* Cardiac pacemaker\n* Cochlear implant\n* Neurological disorders\n* History of traumatic brain injury or neurosurgery","FEMALE","75 Years",{"count":231,"type":22},610,[25],"Fibromyalgia is characterized by widespread pain, fatigue, non-restorative sleep, and psychocognitive alterations, compromising quality of life and leading to absenteeism and early retirement. Up to 70% of patients discontinue treatment with antidepressants and anticonvulsants due to adverse effects or low efficacy, and more than 30% resort to opioid use. Given the treatment challenges and the scarcity of safe alternatives, there is growing interest in interventions such as transcranial direct current stimulation (tDCS), which has shown efficacy in improving symptoms and functionality, with low cost and few side effects. In this context, we designed a randomized, double-blind, double-dummy clinical trial to compare the non-inferiority of 28 home-based anodal tDCS (2 mA) applied over the primary motor cortex (M1) versus duloxetine 60 mg. Both treatments will be combined with physical exercise and pain education. Outcomes will be assessed through multidimensional measures of pain, functionality, global impression of improvement, and the function of the descending pain inhibitory system. Secondary outcomes include quality of life, depressive symptoms, psychophysical pain measures, and treatment adherence. An additional analysis will compare the results of sham tDCS and duloxetine placebo within the non-inferiority model. Predictors of treatment response will also be explored, including symptom severity and oscillatory patterns of cortical electrical activity, rest-activity rhythm, and autonomic function assessed by R-R interval. Furthermore, serum levels of S100-B protein, brain-derived neurotrophic factor (BDNF), and genetic variants related to neuroplasticity in the BDNF Val66Met, Catechol-O-Methyltransferase (COMT) (rs4680) (G\\>A), OPRM1, and PER2 genes will be analyzed. Inflammatory markers (TNF-α, IL-1, IL-2, IL-6, IL-10, C-reactive protein) and serum endorphins will also be assessed. A total of 610 women with fibromyalgia (aged 18 to 75 years) will be randomized into three groups (2:2:1): duloxetine + sham tDCS (n=244); active tDCS + placebo (n=244); and sham tDCS + placebo (n=122). Participants will be assessed during treatment and at 3, 6, and 12 months after completing the intervention protocol. An interim analysis will be conducted when \\~50% of participants (n ≈ 305) complete the 3-month follow-up by an independent, blinded Data Monitoring Committee (DMC). (i) The trial may be stopped if the conditional probability of demonstrating non-inferiority is \\\u003C10%, based on frequentist or Bayesian methods. (i) The trial will be stopped if serious adverse events (SAEs) in the active tDCS group increase by ≥30% compared to duloxetine (p \\\u003C 0.01, adjusted). (ii) Early stopping for efficacy will be considered if active tDCS demonstrates clear non-inferiority or superiority over duloxetine on the primary outcome. Superiority requires: (iii) a clinically relevant difference exceeding the non-inferiority margin (≥10% pain reduction); (ii) statistical significance (p \\\u003C 0.005, O'Brien-Fleming adjusted); and (iii) a ≥2-point (20%) improvement on the BPI, confirmed in the ITT analysis. This study aims to generate evidence to support the decision-making process of the National Committee for Health Technology Incorporation (CONITEC) regarding the availability of tDCS in the Brazilian Unified Health System (SUS). In addition, identifying predictors of response to tDCS and duloxetine, through the integration of genetic, neurophysiological, inflammatory, and psychosocial markers using machine learning algorithms, will allow for identifying factors that can personalize fibromyalgia treatment. This approach enhances clinical efficacy, reduces costs associated with ineffective interventions, and supports more accurate therapeutic decisions, expanding access to safe, effective, and sustainable care within the public healthcare system",[235,236,237,238,31],"Fibromyalgia (FM)","tDCS","Duloxetine","BDNF",[240,241,237,242,243],"Fibromyalgia","Transcranial Direct Current Stimulation","Biomarkers","Precision Medicine","2025-12-31",{"date":150,"type":38},{"date":247,"type":38},"2025-09-30",{"date":152,"type":22},{"name":250,"class":74},"Hospital de Clinicas de Porto Alegre",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":268,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":46},"100614927","mindfulness-walking-intervention-to-enhance-resilience-iwalk-100614927","NCT07285954","Mindfulness Walking Intervention to Enhance Resilience (iWalk)","A Randomized Controlled Trial of a Walking Meditation Intervention (iWalk) to Enhance Resilience in Adults","iWalk","Inclusion Criteria:\n\n1. 18 years or older,\n2. clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc.,\n3. have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs,\n4. never received meditation training via coaching\u002Fcertification\u002Flife coaching,\n5. have internet access,\n6. with no severe cognitive impairment, i.e., have a score of ≥ 21 on Modified Telephonic Interview for Cognitive Status (TICS-M),\n7. be able to walk with or without an assistive device (Patient determined Disease Steps score ranged from 0-6),\n8. are willing to be randomized to an intervention or a control group,\n9. are willing to wear Fitbit (a wrist smart watch) for eight weeks,\n10. are individuals who are right-handed according to the Edinburgh Handedness Questionnaire,\n11. are willing to participate in all assessments, including in-person testing using electroencephalography (EEG) and cognitive tests, online survey\u002Fquestionnaires, and online interviews or focus group discussions,\n12. are willing to wear a Hexoskin t-shirt, which is a heart rate variability monitor, while doing the assessments in person.\n\nExclusion Criteria:\n\nParticipants who cannot speak, read, write, or listen in English.","110 Years",{"count":261,"type":22},90,[25],"This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS).\n\nThe objectives are to evaluate:\n\n1. Recruitment capability and retention rates,\n2. Acceptability and adherence to the intervention,\n3. Feasibility of assessment procedures, and\n4. Preliminary effects on psychological, physiological, and behavioral outcomes.",[265,31,266,267],"Neurodegenerative Disease","Mindfulness","Adults",[269,270,31],"Walking meditation","Emotional regulation","2025-12-02",{"date":273,"type":38},"2025-12-16",{"date":275,"type":38},"2025-06-01",{"date":277,"type":22},"2029-12-31",{"name":279,"class":74},"University of Illinois at Urbana-Champaign",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":290,"conditions":291,"keywords":299,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":311},"100591382","early-wake-up-predictors-after-out-of-hospital-cardiac-arrest-100591382","NCT06979700","Early WAKE-up Predictors After Out-of-Hospital Cardiac Arrest","Early Wake-up Predictors After Out-of-hospital Cardiac Arrest - an Observational, Multicenter Substudy of the DANOHCA Trial","WAKE-OHCA","Inclusion Criteria:\n\n* Age ≥18 years\n* OHCA of presumed cardiac cause\n* Sustained ROSC, defined as persistent signs of circulation and no need for chest compressions or mechanical circulatory support for 20 minutes\n* Unconsciousness (GCS \\\u003C9) (patients not able to obey verbal commands) after sustained ROSC at the time of randomization\n\nExclusion Criteria:\n\n* Females of childbearing potential if pregnancy is suspected (unless a negative HCG test can rule out pregnancy within the inclusion window)\n* Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient)\n* Suspected or confirmed acute intracranial bleeding\n* Suspected or confirmed acute stroke\n* Unwitnessed asystole\n* Known limitations in therapy and Do Not Resuscitate-order\n* Known disease making 180 days survival unlikely\n* Known pre-arrest CPC 3 or 4 functional status\n* \\>3 hours (180 minutes) from ROSC to screening\n* Systolic blood pressure \\\u003C80 mm Hg despite fluid loading\u002Fvasopressor and\u002For inotropic medication (If the systolic blood pressure is recovering during the inclusion window of 180 minutes the patient may be included)\n* Use of intra-aortic balloon pump\u002Faxial flow device\u002FECMO (If the patient is weaned and the device is removed during the inclusion window of 180 minutes the patient may be included)\n* Temperature on admission \\\u003C30°C\n* Known allergy for dexamethasone or olanzapine\n* Ongoing (within 48 h) treatment with olanzapine or dexamethasone\n* Known back or hip condition that precluded the patients from being positioned with backrest from 0 to 45-degree angle\n* Known or suspected Long QT Syndrome (LQTS)\n* Known active fungal disease. Localized skin lesions do not exclude patients from inclusion\n* Estimated body weight \\\u003C45kg",{"count":289,"type":22},250,"WAKE-OHCA is a prospective observational substudy of the Danish Out-of-Hospital Cardiac Arrest (DANOHCA) trial, identifier NCT05895838. The aim is to collect early neuromonitoring data to identify key predictors of successful wake-up.",[292,293,294,31,295,296,297,298],"Cardiac Arrest (CA)","Anoxic Brain Injury","Comatose Survivors of Cardiac Arrest","Pupillometry","Optic Nerve Sheath Diameter","Transcranial Doppler Ultrasound","Neurological Outcome",[300,301],"wakeup","sedation","2025-11-14",{"date":304,"type":38},"2025-11-18",{"date":306,"type":38},"2025-05-13",{"date":308,"type":22},"2027-12",{"name":310,"class":74},"University of Aarhus",2,{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":16,"sex":17,"minAge":319,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":46},"100597159","rural-autistic-individuals---supporting-expression-100597159","NCT07054866","Rural Autistic Individuals - Supporting Expression","RAISE","Inclusion Criteria:\n\n* 1.1 Confirmed (preferably) or suspected diagnosis of ASD (autism spectrum disorder), or a receptive language impairment (i.e., difficulties with comprehension, Developmental Language Disorder), or both. Additional diagnoses, including ADHD (Attention Deficit and Hyperactivity Disorder), are acceptable. Siblings and cousins of these individuals are also welcome.\n\nOR 1.2 No diagnoses of ASD or DLD for unrelated control typically-developing participants.\n\n2\\. Normal hearing and normal vision (or corrected to normal with glasses or contacts).\n\n3\\. Ages 2+. 4. English as the dominant language of caregivers. 5. Caregivers who self-identify as living in a rural area. 6. The ability to verbally or physically respond is optional.\n\nExclusion Criteria:\n\n* 1\\. Poor hearing. 2. Inborn or acquired brain damage.","2 Years",{"count":321,"type":22},50,[25],"This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and\u002For minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \\[cry\\], can promote successful understanding of words like \"cry\". The overarching goal is to help families effectively utilize gestures to support communication with their children.",[325,326,327,328,329,173,330,331,31,136],"Autism Disorder","Language Development Disorders","ADHD","Typical Development","Rural Health","Neuroimaging","Eye Tracking","2025-07-07",{"date":334,"type":38},"2025-07-10",{"date":336,"type":22},"2025-07",{"date":217,"type":22},{"name":339,"class":74},"Montana State University",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":347,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":357,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":46},"100383290","neural-signatures-of-processing-the-temporal-features-of-auditory-events-from-preterm-infancy-to-adulthood-100383290","NCT04270734","Neural Signatures of Processing the Temporal Features of Auditory Events: From Preterm Infancy to Adulthood","PremaTempo","Inclusion Criteria:\n\n* full term neonates between 25 and 36 weeks gestational age\n\nExclusion Criteria:\n\n* Neonates outside the age range","0 Days","1 Day",{"count":350,"type":22},240,[25],"Premature neonates are able to discriminate phonemes and voice from 28wGA at a time the neuronal network establish contact between the environment and the cortical neurones. In the present monocentric study the investigators will analyse the response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography and High Density Near Infrared Spectroscopy.",[354,31,355,356],"Time Perception","Premature Neonates","Discrimination",[358,359,31,136,360,361,362],"time perception","rhythm","ERP","premature neonates","discrimination","2025-06-05",{"date":365,"type":38},"2025-06-10",{"date":367,"type":38},"2020-02-01",{"date":369,"type":22},"2027-02",{"name":154,"class":74},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":347,"maxAge":18,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":46},"100471335","multimodal-analysis-of-the-young-brain-on-rhythm-perception-from-premature-neonates-to-infants-100471335","NCT05417542","Multimodal Analysis of the Young Brain on Rhythm Perception: From Premature Neonates to Infants","Exposition","Inclusion Criteria:\n\n* Full term neonates between 28 and 40 weeks Gestational Age\n\nExclusion Criteria:\n\n* Neonates outside the age range",{"count":379,"type":22},200,[25],"Premature neonates are able to discriminate phonemes and voice from 28wGA at a time the neuronal network establish contact between the environment and the cortical neurones. In the present monocentric study the investigators will analyse the response of the cortical network in premature aged between 28 and 40 wGA in response to auditory stimuli using High Resolution Electroencephalography and High Density Near Infrared Spectroscopy",[354,383,31,136,360,355,356],"Rhythm",[385,359,31,136,360,386,356],"Time perception","Premature neonates","2025-05-22",{"date":389,"type":38},"2025-05-28",{"date":391,"type":38},"2022-05-31",{"date":393,"type":22},"2029-05",{"name":154,"class":74},{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":414,"locationsCount":46},"100585051","comparing-brain-cortical-activity-in-real-and-immersive-virtual-reality-manual-dexterity-tasks-100585051","NCT06897332","Comparing Brain Cortical Activity in Real and Immersive Virtual Reality Manual Dexterity Tasks","Inclusion Criteria:\n\n* Age over 18 years old\n* Normal-to-corrected vision\n* Ability to understand simple instructions\n\nExclusion Criteria:\n\n* History of seizure\n* Recent participation (within the last three months) in a study involving a manual dexterity task in immersive virtual reality\n* Neurologic or orthopaedic pathology potentially affecting upper extremity movement",{"count":402,"type":22},12,"With advances in technology, virtual reality (VR) is increasingly used in various fields, including rehabilitation, motor learning, and neuroscience. Its ability to provide controlled, immersive, and interactive environments makes it a valuable tool for training and assessment. However, despite its growing adoption, limited evidence exists on how cortical activation in VR compares to real-world conditions. Moreover, brain cortical activity during motor tasks, such as manual dexterity tasks, remains underexplored.\n\nThis study aims to compare brain cortical activity in real and immersive virtual reality settings during a manual dexterity task. Secondary objectives include:\n\n* Examining the relationship between brain cortical activity and kinematics in both conditions.\n* Comparing brain cortical activity between hand-tracking and controller-based interactions.",[405,406,31,136,407],"Brain","Virtual Reality","Manual Dexterity","2025-03-20",{"date":410,"type":38},"2025-03-26",{"date":408,"type":22},{"date":413,"type":22},"2025-06-30",{"name":415,"class":74},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":427,"conditions":428,"keywords":434,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":445,"locationsCount":46},"100564990","phase-2-nitrous-oxide-in-the-treatment-of-acute-suicidal-ideation-100564990","NCT06636357","Nitrous Oxide in the Treatment of Acute Suicidal Ideation","NITOS","Inclusion criteria:\n\n* Ability to give written informed consent\n* Moderate to severe suicidal ideation defined as a score ≥3 on the Montgomery-Asberg Depression Rating Scale (MADRS; Schmidtke et al., 1985) suicide item (item #10) as well as a self-report Beck Scale for Suicide Ideation (BSS; Kliem et al., 2017) items #4 plus #5 score ≥ 2\n* Plasma homocysteine level ≤ 14 µmol\u002Fl\n\nExclusion criteria:\n\n* Organic, including symptomatic, mental disorders (F00-F09; lifetime diagnosis)\n* Schizophrenia, schizotypal and delusional disorders (F20-F29; lifetime diagnosis)\n* Mental and behavioral disorders due to psychoactive substance use. Nicotine and cannabis will be ignored (F10-F19)\n* Non-medical (i.e., recreational) use of inhalational N2O during the last 12 months\n* Past intolerance or hypersensitivity to N2O\n* Critical illness\n* Severe cardiac disease\n* Pregnancy or breastfeeding\n* Pulmonary hypertension\n* Chronic cobalamin or folate deficiency unless treated with folic acid and\u002For vitamin B12\n* History or evidence of any other medical or neurological condition that would expose the subject to an undue risk of a significant adverse event as determined by the clinical judgment of the investigator\n* Treatment with ketamine\u002Fesketamine during the last 4 weeks\n* Treatment with opioid medications during the last 3 months\n* Treatment with vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT) within the last 3 months\n* Recent (within the last 4 weeks) or current use of benzodiazepines in excess of 5 mg lorazepam or equivalent per day\n* Finally, any other factors that, in the investigator's judgment, would unduly impact patient safety or compliance during the study.",{"count":424,"type":22},85,[426],"PHASE2","The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.",[429,31,430,431,432,433],"Suicidality","Suicidal Ideation","Nitrous Oxide","Biomarkers \u002F Blood","Biomarkers \u002F Hair",[435,436,437,438],"suicidality","nitrous oxide","suicidal ideation","depression","2025-01-13",{"date":441,"type":38},"2025-01-16",{"date":439,"type":38},{"date":444,"type":22},"2026-09-30",{"name":446,"class":74},"University of Zurich",{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":16,"sex":17,"minAge":453,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":4},"100570249","investigation-of-the-possibility-of-determining-cerebrovascular-disease-based-on-hemodynamic-information-of-localized-brain-regions-100570249","NCT06704789","Investigation of the Possibility of Determining Cerebrovascular Disease Based on Hemodynamic Information of Localized Brain Regions","Inclusion Criteria :\n\n1. For Hemorrhagic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with hemorrhagic stroke through clinical observation and neuroimaging.\n   * First-time hemorrhagic stroke patients.\n   * Hemorrhagic stroke onset between 2 weeks and 12 months prior to screening.\n   * Hemorrhagic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as - antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n2. For Ischemic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with ischemic stroke through clinical observation and neuroimaging.\n   * First-time ischemic stroke patients.\n   * Ischemic stroke onset between 2 weeks and 12 months prior to screening.\n   * Ischemic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n3. For Healthy Adults :\n\n   * Adults aged between 19 and 80 years.\n   * No history of stroke or transient ischemic attack (TIA).\n   * No stroke risk factors such as hypertension, diabetes, or hyperlipidemia.\n   * No chronic diseases (e.g., cardiovascular disease, chronic kidney disease, chronic lung disease).\n   * No psychiatric conditions (e.g., depression, schizophrenia).\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n\nExclusion Criteria :\n\n* History of head trauma in the past 6 months.\n* Ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic lung disease).\n* Severe psychiatric disorders such as schizophrenia, major depression, or bipolar disorder.\n* Use of medications that could influence brain hemodynamics (e.g., antihypertensives, anticoagulants, antiplatelets, or antidepressants).\n* Participation in a study and use of experimental drugs within the past 30 days.\n* Pregnant or breastfeeding women.\n* Major surgery in the past 6 months.\n* Acute infections or inflammatory diseases.\n* Cognitive impairment or dementia.\n* Neurological disorders.\n* Inability to understand the study procedures or unwillingness to provide voluntary consent.\n* Any other clinical concerns deemed inappropriate for participation by the principal investigator or study team.","19 Years","80 Years",{"count":261,"type":22},"The purpose of this study is to compare hemodynamic information from localized brain regions between stroke patients and healthy adults using brain activity data (fNIRS and EEG) and to assess the accuracy of early stroke diagnosis and classification predictions.",[31,458,140,459],"FNIRS","Normal","2024-11-21",{"date":462,"type":38},"2024-11-26",{"date":464,"type":22},"2024-12-01",{"date":244,"type":22},{"name":467,"class":74},"Pusan National University Yangsan Hospital",{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":16,"sex":17,"minAge":453,"maxAge":454,"enrollmentInfo":474,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":482,"locationsCount":4},"100570012","exploratory-study-on-artifact-denoising-of-cerebral-blood-flow-and-eeg-data-in-ambulance-settings-100570012","NCT06701708","Exploratory Study on Artifact Denoising of Cerebral Blood Flow and EEG Data in Ambulance Settings","Inclusion Criteria:\n\n* Healthy adults aged 19 to 80 years.\n* Individuals without chronic diseases (e.g., Stage 2 hypertension, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals without mental health disorders (e.g., depression, schizophrenia, etc.).\n* Individuals not taking medications that could affect cerebral hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.\n\nIndividuals who can read and understand the participant information and consent form and have sufficient language ability to respond to questionnaires.\n\n\\- Individuals who voluntarily decide to participate in the clinical study, provide written consent on the participant consent form, and are able to participate throughout the entire duration of the clinical study.\n\nExclusion Criteria:\n\n* Individuals who have experienced head trauma in the past 6 months.\n* Individuals with ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals with severe mental health disorders such as schizophrenia, severe depression, bipolar disorder, etc.\n* Individuals currently taking medications that may affect the study (e.g., antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.).\n* Individuals who have participated in a clinical trial and taken experimental drugs within the past 30 days.\n* Women who are pregnant or breastfeeding.\n* Individuals who have undergone major surgery in the past 6 months.\n* Individuals with acute infections or inflammatory diseases.\n* Individuals with cognitive impairment or dementia.\n* Individuals with neurological disorders.\n* Individuals who lack understanding of the study procedures or who have not voluntarily consented to participate.\n* Individuals with clinically significant findings that the study principal investigator or responsible medical personnel determines to be inappropriate for participation in this study.",{"count":84,"type":22},"The purpose is to assess the extent of digital noise occurring during the measurement of cerebral blood flow and EEG in healthy adults within an ambulance setting and to explore the possibility of identifying and correcting abnormal patterns.",[459,31,458],"2024-11-20",{"date":479,"type":38},"2024-11-22",{"date":464,"type":22},{"date":244,"type":22},{"name":467,"class":74},{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":507},"100493518","early-neuroprognostication-after-ohca-100493518","NCT05706194","Early Neuroprognostication After OHCA","Early Neurological Prognostication of Outcome After Out-of-hospital Cardiac arrest-a STEPCARE Prospective Substudy","Inclusion Criteria:\n\nAdult cardiac arrest patients with an out-of-hospital cardiac arrest of non-traumatic cause treated at hospitals recruiting patients to the STEPCARE neuroprognostication substudy. Other inclusion criteria include:\n\n* a minimum of 20 minutes without chest compressions\n* Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of \\\u003C4) or being intubated and sedated because of agitation after sustained ROSC\n* Eligible for intensive care without restrictions or limitations\n* Inclusion within 4 hours of ROSC\n\nExclusion Criteria:\n\n* On ECMO prior to randomisation\n* Pregnancy\n* Suspected or confirmed intracranial hemorrhage\n* Previously randomised in the STEPCARE trial\n* Patients with limitations in level-of-care due to for example generalized malignancy","100 Years",{"count":492,"type":22},1000,"This is a prospective observational substudy of the STEPCARE trial ClinicalTrials.gov Identifier: NCT05564754) with the aim to examine whether prognostication of neurological outcome after cardiac arrest can be performed earlier than the 72 h time-point recommended by guidelines today.",[495,298,31,496,497,242],"Cardiac Arrest","CT","Brain Injuries","2024-03-20",{"date":500,"type":38},"2024-03-21",{"date":502,"type":38},"2023-10-01",{"date":504,"type":22},"2029-07-31",{"name":506,"class":74},"Lund University",4,{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":523,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":46},"100534679","high-definition-transcranial-direct-current-stimulation-hd-tdcs-for-refractory-epilepsy-100534679","NCT06241963","High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy","The Efficacy, Safety and Mechanism of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Refractory Epilepsy","Inclusion Criteria:\n\n* Clinical diagnosis of refractory epilepsy\n* Right-handed and aged 18-50 years old and primary school education or above;\n* No major neurological or mental illness, no head injury, alcohol dependence or drug dependence;\n* During the experiment, the subjects did not smoke, drink, get sick and take psychotropic drugs, and there were no major life events that caused mood changes.\n\nExclusion Criteria:\n\n* organic brain injury, neurological diseases or serious physical diseases;\n* Have a history of substance abuse and drug dependence, or have used antipsychotic drugs in the past three months, and have serious suicidal tendencies;\n* There are contraindications for MRI or EEG or transcranial magnetic stimulation.","50 Years",{"count":261,"type":22},[25],"To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.",[241,31,520,521,522],"Functional Magnetic Resonance Imaging","Refractory Epilepsy","Transcranial Magnetic Stimulation",[521,520,31,524],"Transcranial magnetic stimulation","2024-02-15",{"date":527,"type":38},"2024-02-20",{"date":529,"type":22},"2024-02-12",{"date":531,"type":22},"2026-06-30",{"name":533,"class":74},"Anhui Medical University"]